IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 228 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $76,131,824 | -20.3% | 16,732,269 | +23.3% | 0.00% | -20.0% |
| Q2 2023 | $95,503,218 | +13.8% | 13,565,798 | -1.2% | 0.01% | 0.0% |
| Q1 2023 | $83,908,832 | -55.4% | 13,733,033 | -53.3% | 0.01% | -16.7% |
| Q4 2022 | $188,063,770 | +97.6% | 29,430,950 | +196.3% | 0.01% | 0.0% |
| Q3 2022 | $95,150,000 | -26.8% | 9,932,152 | -15.6% | 0.01% | -25.0% |
| Q2 2022 | $129,949,000 | +14.0% | 11,770,751 | +71.9% | 0.01% | +33.3% |
| Q1 2022 | $113,981,000 | +17.2% | 6,845,726 | +34.4% | 0.01% | +20.0% |
| Q4 2021 | $97,238,000 | -10.1% | 5,093,682 | +16.1% | 0.01% | -16.7% |
| Q3 2021 | $108,211,000 | +5.5% | 4,388,106 | +11.3% | 0.01% | +20.0% |
| Q2 2021 | $102,588,000 | +5.4% | 3,942,673 | +28.2% | 0.01% | -16.7% |
| Q1 2021 | $97,375,000 | -27.6% | 3,075,651 | +6.2% | 0.01% | -25.0% |
| Q4 2020 | $134,424,000 | +28.8% | 2,897,079 | -8.6% | 0.01% | +14.3% |
| Q3 2020 | $104,342,000 | +11.7% | 3,169,561 | -6.9% | 0.01% | 0.0% |
| Q2 2020 | $93,403,000 | -29.1% | 3,402,673 | -22.6% | 0.01% | -41.7% |
| Q1 2020 | $131,659,000 | +10.0% | 4,398,171 | +1.7% | 0.01% | +50.0% |
| Q4 2019 | $119,693,000 | +38.2% | 4,324,176 | -9.1% | 0.01% | +33.3% |
| Q3 2019 | $86,600,000 | +3.2% | 4,758,219 | +39.1% | 0.01% | 0.0% |
| Q2 2019 | $83,904,000 | +117.1% | 3,421,866 | -15.8% | 0.01% | +100.0% |
| Q1 2019 | $38,641,000 | -2.5% | 4,063,235 | -9.3% | 0.00% | -25.0% |
| Q4 2018 | $39,641,000 | -11.5% | 4,479,252 | +12.5% | 0.00% | +33.3% |
| Q3 2018 | $44,806,000 | -9.2% | 3,982,562 | +3.3% | 0.00% | -25.0% |
| Q2 2018 | $49,350,000 | +32.6% | 3,855,144 | +75.1% | 0.00% | +33.3% |
| Q1 2018 | $37,217,000 | +143.6% | 2,202,281 | +15.3% | 0.00% | +200.0% |
| Q4 2017 | $15,281,000 | +94.1% | 1,910,512 | +88.1% | 0.00% | 0.0% |
| Q3 2017 | $7,871,000 | +8.0% | 1,015,554 | +2.4% | 0.00% | 0.0% |
| Q2 2017 | $7,286,000 | – | 991,391 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 11,826,299 | $130,562,000 | 4.09% |
| MPM BioImpact LLC | 1,200,000 | $13,248,000 | 3.68% |
| Finepoint Capital LP | 960,200 | $10,601,000 | 3.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,011 | $273,000,000 | 2.85% |
| Avoro Capital Advisors LLC | 9,220,000 | $101,789,000 | 2.01% |
| Long Focus Capital Management, LLC | 1,625,000 | $17,940,000 | 1.88% |
| 683 Capital Management, LLC | 2,000,000 | $22,080,000 | 1.56% |
| Parametrica Management Ltd | 115,870 | $1,268,000 | 1.38% |
| Boxer Capital, LLC | 1,935,133 | $21,364,000 | 1.35% |
| Soleus Capital Management, L.P. | 719,600 | $7,944,000 | 1.24% |